ViiV Healthcare Promotions Took the Lead in the European Antiretrovirals HIV Market in Q4 2025 Q4 2025 gMG Market Driven by Clinical Progress and Regulatory Milestones

ViiV Healthcare and Johnson & Johnson promotional materials came from the Rekambys + Vocabria combination across Europe. It highlighted its approval for adolescents with no resistance to integrase inhibitors. A series of studies demonstrated non-inferior efficacy, while a new visual campaign was presented.

ViiV Healthcare introduced an unbranded HCP campaign to access HIV knowledge online. Long-acting injectables, like Apretude for prevention and Rekambys + Vocabria for treatment, were noted. Dovato promoted its high viral suppression and comparable benefits to triple therapy, while Rukobia advertised its use in patients with multidrug-resistant HIV. Clinical and real-world studies for each brand supported their benefits.